Thomas Hünig

from Wikipedia, the free encyclopedia

Thomas Hünig (born March 4, 1950 in Marburg ) is a German immunologist and developer of the active ingredient TGN1412 .

After studying biology in Würzburg and Heidelberg and a stay at the Massachusetts Institute of Technology , he received his habilitation in 1984 in Würzburg. From 1985 to 1990 he worked at the Max Planck Institute for Biochemistry . Since 1990 he has been a professor at the Institute for Virology and Immunobiology at the University of Würzburg .

In 2000, Hünig and Thomas Hanke founded TeGenero to market the active ingredient TGN1412 he had developed. Incidents occurred during a clinical study that resulted in severe health consequences for six test subjects and the bankruptcy of the company.

Individual evidence

  1. ↑ Curriculum vitae ( Memento of the original from June 25, 2012 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / www.virologie.uni-wuerzburg.de
  2. ↑ faz.de: The shock in the test laboratory , March 26, 2006
  3. ↑ biotechnologie.de: Tegenero case rolled up: Researchers clarify the mechanism of action of the antibody ( memento of the original from July 17, 2010 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , April 4, 2008 @1@ 2Template: Webachiv / IABot / www.biotechnologie.de
personal data
SURNAME Hünig, Thomas
BRIEF DESCRIPTION German immunologist and developer of the active ingredient TGN1412
DATE OF BIRTH March 4th 1950
PLACE OF BIRTH Marburg